• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

糖尿病肾病的现状和最新的治疗趋势。

Current status of diabetic kidney disease and latest trends in management.

机构信息

Division of Endocrinology, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.

出版信息

J Diabetes Investig. 2022 Dec;13(12):1961-1962. doi: 10.1111/jdi.13895. Epub 2022 Aug 24.

DOI:10.1111/jdi.13895
PMID:36001045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9720214/
Abstract

Diabetic kidney disease (DKD) is one of the major microvascular complications of diabetes and is leading cause of end-stage renal disease (ESRD) and one of major risk factors of cardiovascular disease (CVD).

摘要

糖尿病肾病（DKD）是糖尿病的主要微血管并发症之一，是终末期肾病（ESRD）的主要原因，也是心血管疾病（CVD）的主要危险因素之一。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e38/9720214/5bf0bbeaddad/JDI-13-1961-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e38/9720214/5bf0bbeaddad/JDI-13-1961-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e38/9720214/5bf0bbeaddad/JDI-13-1961-g002.jpg

相似文献

1
Current status of diabetic kidney disease and latest trends in management.糖尿病肾病的现状和最新的治疗趋势。
J Diabetes Investig. 2022 Dec;13(12):1961-1962. doi: 10.1111/jdi.13895. Epub 2022 Aug 24.
2
Cardiovascular risk in diabetic end-stage renal disease patients.糖尿病终末期肾病患者的心血管风险。
J Diabetes. 2011 Jun;3(2):119-31. doi: 10.1111/j.1753-0407.2011.00113.x.
3
Diabetic Nephropathy: An Overview.糖尿病肾病概述
Methods Mol Biol. 2020;2067:3-7. doi: 10.1007/978-1-4939-9841-8_1.
4
Gut microbiota and its metabolites - molecular mechanisms and management strategies in diabetic kidney disease.肠道微生物群及其代谢物 - 糖尿病肾病的分子机制和管理策略。
Front Immunol. 2023 Jan 19;14:1124704. doi: 10.3389/fimmu.2023.1124704. eCollection 2023.
5
Chronic Inflammation and Progression of Diabetic Kidney Disease.慢性炎症与糖尿病肾病的进展
Contrib Nephrol. 2019;198:33-39. doi: 10.1159/000496526. Epub 2019 Apr 16.
6
Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease.机器学习算法在 2 型糖尿病合并糖尿病肾病患者终末期肾病风险预测模型中的开发与内部验证。
Ren Fail. 2022 Dec;44(1):562-570. doi: 10.1080/0886022X.2022.2056053.
7
Prognosis and risk factors of chronic kidney disease progression in patients with diabetic kidney disease and non-diabetic kidney disease: a prospective cohort CKD-ROUTE study.患有糖尿病肾病和非糖尿病肾病的患者慢性肾脏病进展的预后和危险因素：一项前瞻性队列 CKD-ROUTE 研究。
Ren Fail. 2022 Dec;44(1):1309-1318. doi: 10.1080/0886022X.2022.2106872.
8
Research progress on extracellular vesicles in the renal tubular injury of diabetic kidney disease.糖尿病肾病肾小管损伤中外泌体的研究进展。
Front Endocrinol (Lausanne). 2023 Sep 4;14:1257430. doi: 10.3389/fendo.2023.1257430. eCollection 2023.
9
Diabetes and cardiovascular disease following kidney transplantation.肾移植后的糖尿病与心血管疾病
Curr Diabetes Rev. 2011 Jul;7(4):221-34. doi: 10.2174/157339911796397857.
10
Associations of lactate dehydrogenase with risk of renal outcomes and cardiovascular mortality in individuals with diabetic kidney disease.乳酸脱氢酶与糖尿病肾病患者的肾脏结局和心血管死亡率风险的相关性。
Diabetes Res Clin Pract. 2023 Sep;203:110838. doi: 10.1016/j.diabres.2023.110838. Epub 2023 Jul 20.

引用本文的文献

1
Machine learning-based prediction of tubulointerstitial lesions in diabetic kidney disease: a multicenter validation study.基于机器学习的糖尿病肾病肾小管间质病变预测：一项多中心验证研究。
Ren Fail. 2025 Dec;47(1):2547266. doi: 10.1080/0886022X.2025.2547266. Epub 2025 Aug 21.
2
Activation of farnesoid X receptor upregulates binding immunoglobulin protein expression and alleviates diabetic nephropathy.法尼醇X受体的激活上调结合免疫球蛋白蛋白表达并减轻糖尿病肾病。
World J Diabetes. 2025 Aug 15;16(8):105228. doi: 10.4239/wjd.v16.i8.105228.
3
Causal impact of elevated body mass index on diabetic kidney disease: an integrated Mendelian randomization and Global Burden of Disease Study 2021 analysis.

本文引用的文献

1
Epidemiological characteristics of diabetic kidney disease in Taiwan.台湾地区糖尿病肾病的流行病学特征。
J Diabetes Investig. 2021 Dec;12(12):2112-2123. doi: 10.1111/jdi.13668. Epub 2021 Oct 3.
2
Acute kidney injury in Japanese type 2 diabetes patients receiving sodium-glucose cotransporter 2 inhibitors: A nationwide cohort study.钠-葡萄糖共转运蛋白 2 抑制剂治疗的日本 2 型糖尿病患者的急性肾损伤：一项全国性队列研究。
J Diabetes Investig. 2022 Jan;13(1):42-46. doi: 10.1111/jdi.13630. Epub 2021 Aug 2.
3
Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial.
体重指数升高对糖尿病肾病的因果影响：孟德尔随机化与2021年全球疾病负担研究的综合分析
Ren Fail. 2025 Dec;47(1):2472981. doi: 10.1080/0886022X.2025.2472981. Epub 2025 Mar 17.
4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.新型糖尿病肾病治疗药物的分子靶点：肾脏保护的新时代。
Int J Mol Sci. 2024 Apr 3;25(7):3969. doi: 10.3390/ijms25073969.
5
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂联合使用对2型糖尿病患者估算肾小球滤过率下降的影响：RECAP研究的事后分析
Front Pharmacol. 2024 Mar 27;15:1358573. doi: 10.3389/fphar.2024.1358573. eCollection 2024.
6
The Role of NF-κB and Bax/Bcl-2/Caspase-3 Signaling Pathways in the Protective Effects of Sacubitril/Valsartan (Entresto) against HFD/STZ-Induced Diabetic Kidney Disease.NF-κB和Bax/Bcl-2/Caspase-3信号通路在沙库巴曲缬沙坦（恩格列净）对高脂饮食/链脲佐菌素诱导的糖尿病肾病保护作用中的作用
Biomedicines. 2022 Nov 9;10(11):2863. doi: 10.3390/biomedicines10112863.
在东亚和东南亚国家，患有 2 型糖尿病和肾病的患者中卡格列净的肾脏、心血管和安全性结局：来自卡格列净和已经存在肾病的糖尿病患者的肾脏评估试验的结果。
J Diabetes Investig. 2022 Jan;13(1):54-64. doi: 10.1111/jdi.13624. Epub 2021 Aug 3.
4
Update on diagnosis, pathophysiology, and management of diabetic kidney disease.糖尿病肾病的诊断、病理生理学和治疗进展。
Nephrology (Carlton). 2021 Jun;26(6):491-500. doi: 10.1111/nep.13860. Epub 2021 Feb 17.
5
Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice.钠-葡萄糖共转运蛋白 2 抑制剂在肾功能损害的 2 型糖尿病患者中可减缓肾功能的年度下降，这在真实临床实践中得到了证实。
J Diabetes Investig. 2021 Sep;12(9):1577-1585. doi: 10.1111/jdi.13502. Epub 2021 Feb 20.
6
High urinary glucose is associated with improved renal prognosis in patients with diabetes mellitus.高尿糖与糖尿病患者的肾脏预后改善相关。
J Diabetes Investig. 2021 Jun;12(6):998-1006. doi: 10.1111/jdi.13428. Epub 2020 Nov 16.
7
Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017.2017 年全球疾病负担研究：1990 年至 2017 年 2 型糖尿病导致的慢性肾脏病流行趋势变化。
J Diabetes Investig. 2021 Mar;12(3):346-356. doi: 10.1111/jdi.13355. Epub 2020 Aug 17.
8
Fractional excretion of tumor necrosis factor receptor 1 and 2 in patients with type 2 diabetes and normal renal function.2 型糖尿病患者肾功能正常时肿瘤坏死因子受体 1 和 2 的分数排泄。
J Diabetes Investig. 2021 Mar;12(3):382-389. doi: 10.1111/jdi.13351. Epub 2020 Aug 10.
9
Randomized trial of an intensified, multifactorial intervention in patients with advanced-stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan).强化多因素干预对晚期糖尿病肾病患者的随机试验：日本糖尿病肾病缓解和回归团队试验（DNETT-Japan）。
J Diabetes Investig. 2021 Feb;12(2):207-216. doi: 10.1111/jdi.13339. Epub 2020 Aug 8.
10
Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets.糖尿病肾病：病理生理学与治疗靶点
J Diabetes Res. 2015;2015:697010. doi: 10.1155/2015/697010. Epub 2015 Apr 30.